LRMR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LRMR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Larimar Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $81.72 Mil. Larimar Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $95.94 Mil.
The historical rank and industry rank for Larimar Therapeutics's Equity-to-Asset or its related term are showing as below:
During the past 5 years, the highest Equity to Asset Ratio of Larimar Therapeutics was 0.88. The lowest was -0.13. And the median was 0.85.
The historical data trend for Larimar Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Larimar Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Equity-to-Asset | -0.13 | 0.86 | 0.82 | 0.88 | 0.85 |
Larimar Therapeutics Quarterly Data | |||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.88 | 0.89 | 0.90 | 0.89 | 0.85 |
For the Biotechnology subindustry, Larimar Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Larimar Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Larimar Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Larimar Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 81.72 | / | 95.935 | |
= |
Larimar Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as
Equity to Asset (Q: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 81.72 | / | 95.935 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Larimar Therapeutics (NAS:LRMR) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Larimar Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Gopi Shankar | officer: Chief Development Officer | C/O LARIMAR THERAPEUTICS, INC., THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA 19004 |
Jeffrey W Sherman | director | C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618 |
Russell Clayton | officer: Chief Medical Officer | 2600 KELLY RD, WARRINGTON PA 18976 |
Carole Ben-maimon | director, officer: President and CEO | C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544 |
Michael Celano | officer: Chief Financial Officer | 220 EAST FIRST STREET, BETHLEHEM PA 18015 |
Joseph Truitt | director | C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511 |
Thomas Edward Hamilton | director | 211 STUYVESANT AVE, RYE NY 10580 |
James E Flynn | 10 percent owner, other: Possible Member of 10% Group | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Jonathan S Leff | director | C/O DEERFIELD MANAGEMENT COMPANY, L.P, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Mgmt Hif, L.p. | director, 10 percent owner, other: Director by Deputization | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Chondrial Therapeutics Holdings, Llc | 10 percent owner | 150 MONUMENT ROAD, SUITE 207, BALA CYNWYD PA 19004 |
Deerfield Mgmt Iv, L.p. | director, 10 percent owner, other: Director by Deputization | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Private Design Fund Iv, L.p. | director, 10 percent owner, other: Director by Deputization | 780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Healthcare Innovations Fund, L.p. | director, 10 percent owner, other: Director by Deputization | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Deerfield Mgmt Iii, L.p. | director, 10 percent owner, other: Director by Deputization | 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
From GuruFocus
By PurpleRose PurpleRose • 07-11-2022
By GuruFocusNews GuruFocusNews • 06-21-2022
By GuruFocusNews GuruFocusNews • 06-11-2022
By GuruFocus Research GuruFocus Editor • 05-19-2023
By GuruFocusNews GuruFocusNews • 07-08-2022
By sperokesalga sperokesalga • 03-28-2023
By PurpleRose PurpleRose • 07-28-2022
By Marketwired • 10-03-2023
By Value_Insider Value_Insider • 11-21-2022
By Stock market mentor Stock market mentor • 02-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.